Σαουδική Αραβία - Αγγλικά - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novartis, switzerland - valsartan,hydrochlorothiazide,amlodipine besilate - film-coated tablet - 160,12.5,10 mg,

Σαουδική Αραβία - Αγγλικά - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novartis, switzerland - valsartan,hydrochlorothiazide,amlodipine besilate - film-coated tablet - 160,25,5 mg,

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - amlodipine besilate 6.94mg equivalent to to 5 mg amlodipine;  ; valsartan 160mg;  ;  ;   - film coated tablet - 5mg/160mg - active: amlodipine besilate 6.94mg equivalent to to 5 mg amlodipine   valsartan 160mg       excipient: colloidal silicon dioxide crospovidone coating premix white coating premix yellow magnesium stearate microcrystalline cellulose purified water - exforge is indicated for the treatment of essential hypertension.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - amlodipine besilate 6.94mg equivalent to to 5 mg amlodipine;  ; valsartan 80mg;  ;  ;   - film coated tablet - 5mg/80mg - active: amlodipine besilate 6.94mg equivalent to to 5 mg amlodipine   valsartan 80mg       excipient: colloidal silicon dioxide crospovidone coating premix white coating premix yellow magnesium stearate microcrystalline cellulose purified water - exforge is indicated for the treatment of essential hypertension.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - amlodipine besilate 13.87mg equivalent to amlodipine 10 mg;  ; hydrochlorothiazide 25mg;  ;  ; valsartan 320mg;  ;  ;  ;   - film coated tablet - 10/320/25mg - active: amlodipine besilate 13.87mg equivalent to amlodipine 10 mg   hydrochlorothiazide 25mg     valsartan 320mg         excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry red 00f15613 opadry yellow 00f12951 - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - amlodipine besilate 6.94mg equivalent to amlodipine 5 mg;  ; hydrochlorothiazide 12.5mg;  ;  ; valsartan 160mg;  ;  ;  ;   - film coated tablet - 5/160/12.5mg - active: amlodipine besilate 6.94mg equivalent to amlodipine 5 mg   hydrochlorothiazide 12.5mg     valsartan 160mg         excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry white 00f18296 - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - amlodipine besilate 6.94mg equivalent to amlodipine 5 mg;  ; hydrochlorothiazide 25mg;  ;  ; valsartan 160mg;  ;  ;  ;   - film coated tablet - 5/160/25mg - active: amlodipine besilate 6.94mg equivalent to amlodipine 5 mg   hydrochlorothiazide 25mg     valsartan 160mg         excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry white 00f18296 opadry yellow 00f12951 - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations.

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - amlodipine besilate; valsartan; hydrochlorothiazide -

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - amlodipine besilate; valsartan; hydrochlorothiazide -

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - amlodipine besilate; valsartan; hydrochlorothiazide -